Cancer diagnostics using blood samples
A normal blood draw is enough to help your doctor detect and classify suspected or diagnosed cancer at various stages of the disease.
Our servicesHow does it work?
If you already have a cancer diagnosis, you and your treating physician should agree that iCellate's service OncoMate® is right for you.
GeneMate® and CellMate® do not require prior physician consultation.
Our services
Inherited cancer risk
Cancer in the family can cause great and sometimes unnecessary concern. From saliva or blood samples, iCellate can analyze the DNA, assess the inherited risk for cancer and suggest actions to take.
Genetic cancer evaluation
iCellate’s genetic cancer evaluation, using circulating tumor DNA (ctDNA), provides detailed genetic tumor information which may reveal targeted treatment options.
Personal cancer screening
Early detection is important for effective cancer treatment. iCellate can, even before symptoms occur, detect the spreading cancer cells through a simple blood test.
What answers can iCellate give?
Inherited cancer risk
Cancer originates from gene mutations in cells. Exposures or habits such as smoking or poor eating habits are well-known risk factors. Mutations may also be inherited.
Of all cancer diagnoses, about 5-10% are hereditary. The risk of developing cancer may be reduced if you take action in time.
If several people in your family have had cancer, especially at an early age, you may want to assess your risk level through our inherited cancer test.
Genetic cancer evaluation
iCellate’s blood biopsies complement the established methods in general healthcare. These new methods are not yet standard in today’s medical care.
iCellate is commited to providing patients with the best possible care through continuous iteration, enhancement and validation of its services.
Personal cancer screening
If cancer is detected early, it is much more likely to be cured. Therefore, it is important that the cancer care of the future adopts methods for early detection.
The number of cancer diagnoses is increasing every year. According to the World Health Organization, 70% more people will be diagnosed with cancer in 2030 compared to today.
iCellate's unique method of testing for circulating tumor cells (CTCs) in the blood is a universal solution for detecting most cancers early. This has been demonstrated in two recent screening studies that can be read here.
Notable awards and grants
R&D collaboration
Roche financed the development of the first prototypes leading to the instrument IsoPic™ and contributed to R&D know-how in the early phases.
R&D collaboration
iCellate entered strategic partnerships with some key affiliates, leading to new discoveries in cell detection automation.
Guide treatment
The AFA grant resulted in a more robust way to handle CTCs while keeping DNA intact and novel techniques to extract and amplify DNA from a single cell.
Verification
iCellate was awarded the ”Vinn verifiering” by Vinnova that resulted in early verification of the CTC isolation technique.